SCHEMBL4706540

SCHEMBL4706540

CC1C(C2CCCN(c3ccc(F)cc3F)C2)OCCN1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
CHRM4 P08173 1/20 0.38
MAPT P10636 5/20 0.37
HPGD P15428 5/20 0.37
RAB9A P51151 4/20 0.37
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
GAA P10253 2/20 0.37
NPC1 O15118 4/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ACACB O00763 1/20 0.36
TSHR P16473 2/20 0.35
HSD11B1 P28845 1/20 0.35
GRM5 P41594 1/20 0.35
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4756500 0.91 HPGD (0.40) HTTMAPTHPGDRAB9AALDH1A1
SCHEMBL5659856 0.78 HTT (0.39) KDM4EHTTCHRM4MAPTHPGD
SCHEMBL4757474 0.74 KDM4E (0.39) KDM4EHTTCHRM4MAPTALDH1A1
SCHEMBL4823139 0.70 CCR1 (0.46) MAPTHPGDRAB9AALDH1A1SMN1; SMN2
SCHEMBL4823799 0.69 CCNE1 (0.41) KDM4EHTTCHRM4MAPTALDH1A1
SCHEMBL4706542 0.68 KDM4E (0.37) KDM4EHTTCHRM4MAPTHPGD
SCHEMBL4706042 0.68 HTT (0.49) KDM4EHTTMAPTRAB9AALDH1A1
SCHEMBL29165103 0.68 LMNA (0.46) MAPTMEN1KMT2AGRM5
SCHEMBL27154017 0.68 LMNA (0.46) MAPTMEN1KMT2AGRM5
SCHEMBL5661256 0.67 CCR1 (0.41) KDM4EHTTMAPTHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979318-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-10-15 EP claimed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US claimed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO claimed
EP-1979318-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-10-15 EP disclosed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197530-A1 Amido compounds and their use as pharmaceuticals HSD11B1, HSD17B11, CYP11B1 KDM4E 2999/4885HTT 2385/4885CHRM4 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.